Conference Call with Ipca Laboratories Management and Analysts on Q3FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Ipca Laboratories announced Q3FY26 results Consolidated Financial Highlights: Consolidated Net total Income up 7% at Rs 2,412.69 crore. Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 22.15% in Q3FY26 as against @ 19.87% in Q3FY25. Consolidated Net Profit at Rs 326.27 crore (after exceptional items) up 31%. Exports Income up 13% at Rs 770.49 crore. Standalone Financial Highlights: Standalone Net total Income up 11% at Rs 1,863.00 crore. Standalone EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 26.09% in Q3FY26 as against @ 24.25% in Q3FY25. Standalone Net Profit at Rs 303.45 crore (after exceptional items) up 13%. Indian formulations income up 12% at Rs 984.00 crore. Result PDF
